Grateful for the opportunity to collaborate at @Research_Inter with colleagues including @DrBenjaminHorne to understand how to best mitigate post-discharge thrombosis risk for hospitalized medical patients at featured in @CleClinicMD : https://t.co/FUiwcp6Jyu @Jess_Intermtn
Congratulations to the @ACPIMPhysicians Utah Chapter Scientific Meeting for another amazing Scientific Meeting. Dr. Charlene Dewey, MD MACP from @VUMChealth provides a stellar keynote speech. @UofUInternalMed so well represented along with @Intermountain physician educators!
Methods of a cluster-randomized, type II hybrid implementation effectiveness trial to prospectively assess extended-duration thromboprophylaxis for at-risk medical patients being discharged to prevent venous thromboembolism @SCWollerMD@RPTHjournal https://t.co/8ElqOsUuFq
If you are looking for great resources and handouts to share the colleagues, patients, their families, check out @thrombosisday@ThrombosisCan@AnticoagForum @NATFthrombosis @ThrombosisUK @ThrombosisIrL and many, many others!
Congratulations to @AmikoUchidaMD and mentor Kathryn Peterson, MD, MSCI, for their recent study published in @JAMANetwork on eosinophilic gastrointestinal diseases. Explore their findings here: https://t.co/36yMoiHM7c #uofuhealth#internalmedicine#gastroenterology
What is the risk of #VTE recurrence for patients presenting with distal #DVT? It’s low, but meaningful over 5-10 years. Strength of index provoking risk factor was a strong predictor of recurrence. approx 2/3red we’re proximal DVT or PE. #ISTH2023
🚨Paul Dobesh presenting some compelling data for use of Andexanet Alpha at #ISTH2023
Retrospective review comparing 4F-PCC (mean dose 2510units) to Andexanet (~2/3 low dose)
🌟Use if Andexanet Alpha led to a 50% decrease in in-house mortality. (1/3)
What was that? Chairs of the Councils of Early Career Physicians, Resident/Fellow Members, and Student Members are all women?
Mmmhmmmm that’s what I’m talking about!!
@ACPIMPhysicians#IMProud#IM2023